203 related articles for article (PubMed ID: 14508076)
1. Novel anticancer agents in clinical development.
Adjei AA; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S5-15. PubMed ID: 14508076
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction pathway targets for anticancer drug discovery.
Adjei AA
Curr Pharm Des; 2000 Mar; 6(4):361-78. PubMed ID: 10788587
[TBL] [Abstract][Full Text] [Related]
3. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in gynecologic cancers.
Chon HS; Hu W; Kavanagh JJ
Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
[TBL] [Abstract][Full Text] [Related]
5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of target of rapamycin inhibitors.
Easton JB; Houghton PJ
Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
[TBL] [Abstract][Full Text] [Related]
7. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
Zajac M; Muszalska I; Jelinska A
Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
[TBL] [Abstract][Full Text] [Related]
8. Novel pharmacological agents in clinical development for solid tumours.
Dy GK; Haluska P; Adjei AA
Expert Opin Investig Drugs; 2001 Dec; 10(12):2059-88. PubMed ID: 11772306
[TBL] [Abstract][Full Text] [Related]
9. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
10. Molecular approach to breast cancer treatment.
Yarden Y; Baselga J; Miles D
Semin Oncol; 2004 Oct; 31(5 Suppl 10):6-13. PubMed ID: 15490369
[TBL] [Abstract][Full Text] [Related]
11. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD; Buckner JC; Sarkaria JN
Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
[TBL] [Abstract][Full Text] [Related]
13. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
15. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.
Tortora G; Ciardiello F
Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
17. Raf kinase as a target for anticancer therapeutics.
Sridhar SS; Hedley D; Siu LL
Mol Cancer Ther; 2005 Apr; 4(4):677-85. PubMed ID: 15827342
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
Spänkuch B; Strebhardt K
Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]